Clinical Trials Sponsored by Genomas, Inc

Total 36230 results

Oryzon Genomics S.A.

Completed

Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population

Borderline Personality Disorder

Spain, Serbia, United States, Germany, Bulgaria
American Genomics, LLC

Completed

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

Anesthesia, Local

United States
Quantum Genomics SA

Completed

Firibastat in Treatment-resistant Hypertension (FRESH)

Hypertension

United States, Czechia, France, Germany, Poland, Spain
Quantum Genomics SA

Completed

Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension (2QG1)

Essential Hypertension

France
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
Genmab
AbbVie

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Belgium, Brazil, China, United States, Canada and more
Genmab
AbbVie

Approved for marketing

Expanded Access Program for Epcoritamab

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
AbbVie
Genmab

No longer available

Expanded Access to Epcoritamab

Lymphoma
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Attention Deficit Hyperactivity Disorder

United States
Quantum Genomics SA

Completed

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction (QUORUM)

Myocardial Infarction

Poland, Germany, France, Hungary, Slovakia, Spain, United Kingdom
Clinical Genomics Pathology

Completed

Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL (PASCAL)

Colorectal Cancer

United States
Quantum Genomics SA

Terminated

QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF (QUID-HF)

Heart Failure

France, Germany, Netherlands, United Kingdom, Hungary, Norway, Czechia, Poland
Quantum Genomics SA

Completed

Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects

Essential Hypertension

France
University of Puerto Rico
National Institute on Minority Health and Health Disparities (NIMHD); Genomas...

Completed

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

Atrial Fibrillation | Deep Vein Thrombosis | Pulmonary Embolism | Cardiac Valvular Insufficiency | Coagulopathies

United States, Puerto Rico
Fondazione Sandro Pitigliani
Genomic Health®, Inc.; Istituto Toscano Tumori

Active, not recruiting

Probability of OncotypeDx to Reallocate as Low or High Risk of Recurrence Breast Cancer Patients With Uncertain Biology

Breast Cancer

Italy
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

22q11.2 Deletion Syndrome

United States
HemoShear Therapeutics
Prometrika, LLC; AllStripes Research Inc.; Genome Medical

Terminated

Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia (JUMP)

Propionic Acidemia | Methylmalonic Acidemia

United States, Canada, United Kingdom
Selecta Biosciences, Inc.
National Human Genome Research Institute (NHGRI)

Suspended

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA (reiMMAgine)

Methylmalonic Acidemia (MMA)

United States
Assistance Publique - Hôpitaux de Paris
Human Genome Sciences Inc.

Completed

Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome (BELISS)

Sjögren's Syndrome

France
Genome & Company

Not yet recruiting

A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
Genmab
AbbVie

Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

United States, Australia, France, Israel, Korea, Republic of, Spain, Taiwan, Japan, Italy, Belgium, Germany, Canada, Turkey, Czechia
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Genmab
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma

China
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Genmab
AbbVie

Terminated

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Esophageal Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer (NSCLC) | Uterine Cancer | Triple Negative Breast Cancer (TNBC) | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Locally Advanced or Metastatic Solid Tumor(s)

Spain, Israel, United States, Denmark
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Unknown

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

Radiation Pneumonitis
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Acute Lung Injury | ARDS | COVID-19 Pneumonia

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Unknown

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

China
American Genomics, LLC

Completed

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Anesthesia, Local

United States
American Genomics, LLC

Completed

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Anesthesia, Local

United States
American Genomics, LLC

Completed

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Anesthesia, Local

United States
American Genomics, LLC

Completed

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Healthy

United States
Clinical Genomics Pathology

Completed

Colvera for Detection of Disease Recurrence (NOVA)

Colorectal Adenocarcinoma

United States
Quantum Genomics SA

Completed

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins (NEW-HOPE)

Hypertension

United States
Quantum Genomics SA

Completed

Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo

Essential Hypertension

France
Clinical and Translational Genome Research Institute...
Children's Specialized Hospital

Terminated

Pharmacogenomics for Improving Pediatric ADHD Treatment

Attention Deficit Disorders With Hyperactivity

United States
Hospital for Special Surgery, New York
Human Genome Sciences Inc.

Completed

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis

United States
University of Genova

Recruiting

Brain Recovery With Automated VEntilation (BRAVE)

Respiration, Artificial | Automation | Brain Injuries, Acute

Italy
Genoss Co., Ltd.

Recruiting

Evaluating Efficacy and Safety of 1-year of DAPT After Genoss DES Sirolimus-eluting Stent Implantation in Patients (DAPTLONG)

Coronary Artery Disease | Percutaneous Coronary Intervention | Dual Antiplatelet Therapy

Korea, Republic of
Genoss Co., Ltd.

Recruiting

Prospective Registry of Patients With Acute Coronary Syndrome Treated With GENOSS Stent (GENOSSACS)

Acute Coronary Syndrome | Percutaneous Coronary Intervention

Korea, Republic of
Genoss Co., Ltd.

Recruiting

Evaluating Efficacy and Safety of GENOSS Stent in Patients With Coronary Artery Disease (GENOSSDES)

Coronary Artery Disease

Korea, Republic of

Clinical Trials Sponsored by Genomas, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations